3
Announcements
Trials
Browse
Landscape
Phase
Phase 1/2
1
Status
Recruiting
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Genitourinary
1
Conditions
Prostatic Neoplasms
19
Urinary Bladder Neoplasms
1
Recurrence
1
Prostatic Neoplasms, Castration-Resistant
1
Prostate Cancer, Hereditary, 7
1
Nonseminomatous germ cell tumor
1
Neoplasms
1
Neoplasm Metastasis
1
Metastatic Castration-resistant Prostate Neoplasms
1
Metastatic Castration-resistant Prostate Cancer
1
Carcinoma, Transitional Cell
1
Adenocarcinoma
1
Interventions
enzalutamide
10
Prednisone
6
Docetaxel
5
Abiraterone Acetate
4
darolutamide
3
olaparib
2
niraparib
2
abiraterone
2
Pluvicto
2
zimberelimab
1
xentuzumab
1
sacituzumab govitecan
1
radium Ra 223 dichloride
1
quemliclustat
1
ibrutinib
1
gedatolisib
1
gallium 68 PSMA-11
1
fludrocortisone acetate
1
cabazitaxel
1
TVB-2640
1
Rosuvastatin Calcium
1
Pioglitazone
1
Omeprazole
1
Nivolumab
1
JNJ-64619178
1
JNJ-64264681
1
Ipilimumab
1
Gonadotropin-Releasing Hormone
1
Dexamethasone
1
CTLA-4 Antigen
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Prostatic Neoplasms, Castration-Resistant
×
cabazitaxel
×
1 year
×
Clear all
NCT06353386
2026-05-26
MK-5684-01A
Merck Sharp & Dohme LLC
Phase 1/2
Recruiting
220 enrolled